Drug intelligence / Profile preview

CDC-801

Development stage: Phase 2
Lead developer: Bristol Myers Squibb
Modality: Small Molecules
Administration: Oral

Overview

CDC-801 is a small molecule drug classified as a selective cytokine inhibitory drug (SelCID) and an analog of thalidomide. It acts as a potent and orally active inhibitor of phosphodiesterase 4 (PDE4) and tumor necrosis factor-alpha (TNF-alpha), with IC50 values of 1.1 μM for PDE4 and 2.5 μM for TNF-alpha[1][2]. By inhibiting PDE4, CDC-801 reduces the production of pro-inflammatory cytokines such as TNF-alpha, vascular endothelial growth factor (VEGF), and interleukin 6 (IL-6). This mechanism underlies its potential antineoplastic and anti-inflammatory activities. The drug has been investigated in clinical trials for chronic lymphocytic leukemia and Crohn's disease[2][3][8].

Other names: UNII-95HB56U8P8UNII95HB56U8P8UNII 95HB56U8P83-(3-(cyclopentyloxy)-4-methoxyphenyl)-3-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)propanamide

Targets

PDE4APDE4B (3',5'-cyclic-AMP phosphodiesterase 4B)

Beyond the preview

Go deeper on CDC-801.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CDC-801.

Explore the full profile